Seeking Alpha

Synta Pharmaceuticals (SNTA) -30% and extending its losses from AH trading yesterday after...

Synta Pharmaceuticals (SNTA) -30% and extending its losses from AH trading yesterday after disclosing mixed interim results from a Phase IIb/III trial of its ganetespib treatment for lung cancer. Synta is assessing the drug in combination with docetaxel, a leading chemotherapy.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)